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49Inhibin removes the inhibitory effects of activin on steroid
enzyme expression and androgen production by normal
ovarian thecal cellsJ M Young and A S McNeilly
MRC Human Reproductive Sciences Unit, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
(Correspondence should be addressed to J M Young, who is now at Monash Institute of Medical Research, Centre for Reproduction and Development, 27–31 Wright Street, PO Box
5418, Clayton, VIC 3168, Australia; Email: julia.m.young@monash.edu)AbstractActivin and inhibin are important local modulators of theca cell steroidogenesis in the ovary. Using a serum-free primary
theca cell culture system, this study investigated the effects of inhibin on theca cell androgen production and expression
of steroidogenic enzymes. Androstenedione secretion from theca cells cultured in media containing activin, inhibin and
follistatin was assessed by RIA over 144 h. Activin (1–100 ng/ml) suppressed androstenedione production. Inhibin
(1–100 ng/ml) blocked the suppressive effects of added activin, but increased androstenedione production when added
alone, suggesting it was blocking endogenous activin produced by theca cells. Addition of SB-431542 (activin receptor
inhibitor) and follistatin (500 ng/ml) increased androstenedione production, supporting this concept. Infection of theca
cells with adenoviruses expressing inhibitory Smad6 or 7 increased androstenedione secretion, confirming that the
suppressive effects of activin required activation of the Smad2/3 pathway. Activin decreased the expression levels of
steroidogenic acute regulatory protein (STAR), whereas STAR expression was increased by inhibin and SB-431542,
alone and in combination. CYP11A was unaffected. The expression of CYP17 encoding 17a-hydroxylase was unaffected
by activin but increased by inhibin and SB-431542, and when added in combination the effect was further enhanced. The
expression of 3b-hydroxysteroid dehydrogenase (3b-HSD) was significantly decreased by activin, while inhibin alone and
in combination with SB-431542 both potently increased the expression of 3b-HSD. In conclusion, activin suppressed
theca cell androstenedione production by decreasing the expression of STAR and 3b-HSD. Inhibin and other blockers of
activin action reversed this effect, supporting the concept that endogenous thecal activin modulates androgen production
in theca cells.Journal of Molecular Endocrinology (2012) 48, 49–60Introduction
Female fertility relies on a tightly controlled balance
of hormonal signals and cellular interactions that
result in the successful production of a mature oocyte
for fertilization. Of these hormones, estradiol is a vital
component required for oocyte maturation (Tesarik &
Mendoza 1995). It is synthesized in granulosa cells
from androgen precursors produced by theca cells
that surround developing antral follicles, and is
produced in increasing quantities by the growing
follicle as development reaches the preovulatory stage
(Young & McNeilly 2010). Before the expression of
aromatase in granulosa cells, follicles are exposed to
varying levels of androgens derived from thecal cells
largely under the control of LH.
In vitro, testosterone inhibits meiotic maturation of
the oocyte and subsequent embryo development
(Laufer et al. 1984, Anderiesz & Trounson 1995). This
negative effect of androgens would potentially be
neutralized in vivo by expression of aromatase in the
cumulus granulosa cells surrounding the oocyte in theJournal of Molecular Endocrinology (2012) 48, 49–60
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reproduction in any medium, provided the original work is properly cited.preovulatory follicle, thus reducing exposure to these
potentially damaging effects of excess testosterone
and androgens.
In rodents, androgens not only can induce follicular
atresia (Hillier & Ross 1979, Daniel & Armstrong
1986, Billig et al. 1993) but also have been shown to
promote follicular development (Murray et al. 1998)
and upregulate FSH-receptor expression in granulosa
cells in culture (Tetsuka & Hillier 1997). In primates,
intermittent exposure to androgens in normal female
monkeys resulted in accelerated early stages of ovarian
follicle development with reduced granulosa cell
atresia and increased thecal cell mass, and enhanced
granulosa cell FSH-receptor expression (Vendola et al.
1998, Weil et al. 1999). In contrast, chronic exposure
led to intermittent or absent menstrual cycles (Billiar
et al. 1985, Faiman et al. 1988). Thus, excess androgen
production at an inappropriate time could directly
affect the rates of follicle activation and lead to
premature loss of primordial follicles.
In polycystic ovary syndrome (PCOS), follicle
development is stalled, and a major characteristic isDOI: 10.1530/JME-11-0134
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an intrinsic ability of thecal cells to produce increased
levels of androgens (Gilling-Smith et al. 1994, 1997,
Nelson et al. 1999, 2001, Nelson-Degrave et al. 2005). It
has been suggested that androgen-induced expression
of insulin-like growth factor 1 (IGF1) and its receptor in
early growing follicles may predispose thecal cells to
produce more androgens (Vendola et al. 1999), while
MEK/ERK phosphorylation has been shown to be
decreased in thecal cells from patients with PCOS
compared with normal subjects (Nelson-Degrave et al.
2005). This excess androgen itself has been implicated
in the failure of follicles to continue to grow in PCOS.
In spite of these studies, the modulation of androgen
secretion by thecal cells from small antral stages as
follicles develop into a preovulatory follicle during
normal reproductive cycles is still unclear (Young &
McNeilly 2010). Previous studies have shown that both
BMPs (Glister et al. 2005, Campbell et al. 2006) and
activin (Hillier et al. 1991a) can reduce androgen
secretion from primary cultures in vitro. Furthermore, it
was shown that inhibin alone could ‘stimulate’ andro-
gen production and also neutralize the effects of added
activin by human theca cells (Hillier et al. 1991b).
However, there is no evidence that inhibin has a
receptor coupled to any second messenger signaling
pathway, but instead binds to betaglycan and the type 2
activin receptor to block the effects of activins (Lewis
et al. 2000). Given that this is the case, the real effects of
inhibin would then be to block the intrinsic inhibitory
effects of activins that presumably are being produced
by the thecal cells themselves. In this study, we have
sought to clarify the role of inhibin on thecal cell
androgen production by normal thecal cells main-
tained in primary cultures in conditions that prevent
luteinization, thus mimicking the situation during
normal follicle development. Using adenoviral vectors,
follistatin and a specific chemical activin receptor
blocker (SB-431542), we have shown that inhibin acts
only as an activin inhibitor, rather than ‘stimulating’
androgen production. Instead inhibin removes the
activin-induced brake on androgen production.Materials and methods
Primary theca cell culture
Ovaries were obtained from sheep throughout the year
and transferred to the laboratory in Medium 199
containing 20 mmol/l HEPES, 100 kIU/l penicillin,
0.1 ng/ml streptomycin and 1 mg/l amphotericin
(Fungizone; all supplied by Sigma–Aldrich). Small
follicles (!3.5 mm in diameter) were dissected from
ovaries in Dulbecco’s PBS without calcium or mag-
nesium, with particular attention given to removal of allJournal of Molecular Endocrinology (2012) 48, 49–60extraneous stromal tissues surrounding the thecal
layers. Follicles were then hemisected, and washed
vigorously using a 1 ml syringe, flushing repeatedly to
separate granulosa cells from the thecal cells as
described previously (Campbell et al. 1996). The thecal
cells were then dispersed in an enzyme mixture
containing 10 ml PBS, 5 g/l collagenase, 1 g/l hyalur-
onidase, 1 g/l protease and 0.001% donor calf serum
(vol/vol) for w10 min at 37 8C with gentle agitation.
The reaction was stopped by addition of 2 ml FCS, and
cells were then washed by centrifugation at 800 g for
5 min and resuspended in culture media (DMEM-F12
with 100 kIU/l penicillin, 0.1 mg/l streptomycin,
3 mmol/l L-glutamine, 0.1% BSA (w/vol), 2.5 mg/l
transferrin, 4 mg/l selenium, 10 ng/ml bovine insulin
and 10 ng/ml LR3 IGF1). Ovine LH (code #AFP 8614B-
NHPP-NIDDK supplied by Dr A Parlow, NHPP, Harbor-
UCLA, Torrance, CA, USA) was also added to all culture
media at 0.1 ng/ml ovine LH, unless otherwise stated.
The cell pellets were then resuspended in culture
media, and after a further wash, the number and
viability of the cells were estimated using Trypan Blue
exclusion. Cell viability was routinely more than 95%.
Cells were plated in 96-well plates at 75 000 cells in a
total of 200 ml media/well. Various concentrations and
combinations of ligand and chemical treatments were
added to the media in quadruplicate, and the exact
details are given in the ‘Results’ section. Activin A (code
#338-AC) and follistatin (code #669FO/CF) were
obtained from R & D Systems (Abingdon, Oxon, UK),
inhibin A was from NIBSC (code #91/624, Hertford-
shire, UK) and SB-431542 was supplied by Sigma–
Aldrich. Cells were cultured under standard culture
conditions consisting of a humidified atmosphere with
5% CO2 at 37 8C. For hormone analysis, cells were
cultured for up to 6 days and the media changed every
48 h and stored at K20 8C for analysis at a later stage.
At the end of the culture period, the cell viability was
determined by Neutral Red dye uptake as described
elsewhere (Campbell et al. 1996).Adenovirus transfection
Recombinant adenoviruses were constructed from
pcDNA3–Smad6, and pcDNA3–Smad7 expression
plasmids obtained from Dr P Ten Dijke (The Nether-
lands Cancer Institute, Amsterdam, The Netherlands),
as described previously (Fujii et al. 1999, Nakao et al.
1999), and were a generous gift from Dr Aristidis
Moustakas (Ludwig Institute for Cancer Research,
Uppsala, Sweden). Thecal cells were isolated and
dissociated enzymatically as previously described and
were plated in culture media under standard culture
conditions at 75 000 cells/well and incubated over-
night to allow cell attachment. The following day,
all media were removed, infection of recombinantwww.endocrinology-journals.org
Table 1 Forward and reverse primer sequences for quantitative
RT-PCR and respective amplicon size
Gene
(accession) Nucleotide sequence (5 0–3 0)
Product
size (bp)
GAPDH (NM_001034034) 229
Inhibin removes inhibitory effects of activin . J M YOUNG and A S MCNEILLY 51adenoviruses was performed at concentrations of 10, 50
and 100 plaque-forming units (pfu)/cell overnight, and
then the following day, the cells were resuspended in
200 ml culture mediaGappropriate ligands/treatments.
The culture media were then changed every 48 h up to
144 h, and stored at K20 8C for RIA.Forward GGCGTGAACCACGAGAAGTATAA
Reverse AAGCAGGGATGATGTTCTGG
STAR (NM_001009243) 194
Forward GCATCCTCAAAGACCAGGAG
Reverse CTTGACACTGGGGTTCCACT
CYP17 (NM_001009483) 215
Forward AGACATATTCCCTGCGCTGA
Reverse GCAGCTTTGAATCCTGCTCT
3b-HSD (NM_001135932) 200
Forward GGAGACATTCTGGATGAGCAGSteroid assays
Concentrations of androstenedione were determined
from non-extracted cell culture media by a previously
described RIA method (Campbell et al. 1998). The
sensitivity of the androstenedione assay wasw5 pg/ml,
and the inter- and intra-assay variation was !15%.Reverse TCTATGGTGCTGGTGTGGA
CYP11A (NM_001093789) 172
Forward CAGGAGGCAGTAGAGGATGC
Reverse CAACGTCCCTCCAGAACTGT
Id1 (NM_001097568) 151
Forward TCTGGGATCTGGAGTTGGAG
Reverse ATACGATCGTCCGCTGGAAQuantitative RT-PCR
Thecal cell cultures for RNA collection were established
as described above, but were plated at w750 000
cells/well in six-well plates and left to attach overnight.
Treatments were added in fresh media the following day
and left to incubate under standard culture conditions.
After 24 h, another dose of ligand was added to the
same media, and then again at 48 h. After the final dose
was added at the 48 h time point, cells were incubated
for a further 1 h, then media removed and stored at
K20 8C for RIA, and cells lysed and RNA extracted
using the Qiagen RNeasy Micro RNA extraction kit.
RNA concentration and purity (A260/A280 ratio) were
measured using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific). RNA was stored at K80 8C
until cDNA was synthesized from 200 ng total RNA per
reaction using Superscript VILO cDNA synthesis kit
(Invitrogen) in a 20 ml reaction.
Primer sets for expression analysis were designed
to amplify short regions of the target genes crossing
an intron/exon boundary and are listed in Table 1.
The primers were pre-validated using conventional PCR
and the product was sequenced to confirm authenticity.
Quantitative RT-PCR (qRT-PCR) was carried out using
Power SYBR Green (Applied Biosystems), whereby
the primer efficiency was determined by generating
standard curves. A 10 ml final reaction volume was
prepared using 1 ml synthesized cDNA, 2! Power SYBR
Green PCR Master Mix, 5 mM primer pairs, and
nuclease-free water. The qRT-PCR cycling program
consisted of a denaturing step (95 8C for 10 min),
annealing and extension step (95 8C for 15 s and 60 8C
for 1 min) repeated 40 times, and a dissociation step
(95 8C, 60 8C and 95 8C for 15 s each), using a real-time
thermal cycler from Applied Biosystems (ABI-7500).
Each sample was measured in duplicate, and negative
controls included a reaction using cDNA prepared
leaving out reverse transcriptase and a reaction
substituting cDNA with nuclease-free water. The relativewww.endocrinology-journals.orgexpression level of each target gene to GAPDH was
quantified by the DDCt method. Data were presented as
averageGS.E.M. and the statistical analysis was per-
formed using the Student’s t-test. P values !0.05 were
regarded as significant, and levels of significance were
indicated on graphs for each gene analyzed.Statistical analysis
For each cell culture experiment, cells from at least four
sheep were pooled and treatments carried out in
quadruplicate. The significance of treatment effects
was determined by ANOVA, and individual compari-
sons between treatments were made using Student’s
t-test. All hormone data were expressed as picograms
of hormone per microliter of cell culture media.Results
In this study, activin receptors (types IA, IB, IIA and
IIB), Smad2/3, and the putative inhibin co-receptor
betaglycan (transforming growth factor (TGF) bRIII)
were identified in ovine theca and granulosa cells
during folliculogenesis (data not shown).Activin suppressed androgen secretion
The effects of activin A at 1, 10 and 100 ng/ml on thecal
androgen production are shown in Fig. 1A. Activin A
was a potent inhibitor of androstenedione production
from ovine thecal cells in vitro and was highly effective at
the lowest dose tested (1 ng/ml). Viability evaluated by
Neutral Red assay on completion of culturing at 144 hJournal of Molecular Endocrinology (2012) 48, 49–60
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Figure 1 Androstenedione production in theca cell cultures (A)
in the presence of 0–100 ng/ml activin A and (B) effects of inhibin A
on theca androstenedione production. Cell culture media were
replaced every 48 h and androstenedione secreted into spent media
was evaluated by RIA. Results show averageGS.E.M. Data provided
are representative of at least four experiments, of which each
experiment contained a separate pool of cells (nZ4–5 sheep per
pool), *P!0.05 and ***P!0.001 compared with the control group.
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Analyses also showed that theca cells maintained
androgen production during the last 48 h culture
period, indicating good health and steroidogenic
capabilities. Furthermore, progesterone output
measure by RIA (data not shown) remained at initial
control levels throughout the culture period, indicating
a lack of luteinization in the culture conditions as
expected (Campbell et al. 1998).Figure 2 Androstenedione production from theca cells in the
presence of activin (10 ng/ml), inhibin (100 ng/ml) and both factors
added together. Results give data of the averageGS.E.M. of four
replicate wells of pooled theca cells from four sheep, androste-
nedione was measured by RIA. *P!0.5 and ***P!0.001
compared with the control group.Inhibin increased androgen production
Inhibin increased (P!0.001) androstenedione pro-
duction from theca cells cultured in vitro (Fig. 1B).Journal of Molecular Endocrinology (2012) 48, 49–60Results show a potent response to inhibin, which was
highly effective at the lowest dose evaluated (1 ng/ml).
Inhibin added alone is likely to act by blocking the
suppressive effects of endogenously produced activin,
and possibly also acts on BMPs that may be produced by
theca cells in vitro (Wiater & Vale 2003).Inhibin blocked the suppressive effects of activin
on theca steroidogenesis
Inhibin blocked the suppressive effects of added
activin on theca androstenedione production at
144 h but not at 96 h (Fig. 2). The effects of inhibin
became more significant over time, and on completion
of the culture, inhibin antagonized (P!0.001) activin
suppression.Activin receptor inhibitor stimulated steroidogenesis
The small molecule inhibitor SB-431542 is a potent
and specific inhibitor of activin receptors type IB
(ALK4), TGFbRI (ALK5) and activin receptor type IC
(ALK7) (Inman et al. 2002). In this experiment, the
effects of this chemical activin receptor inhibitor were
compared with those of inhibin. The manufacturer’s
instructions indicate that 10 mM SB-431542 is required
for complete ablation of Smad2 phosphorylation by
activin receptors IB, IC and TGFbRI. A dose response
was therefore established from 0.1 to 10 mM, and the
total androstenedione produced over time in culture
is shown in Fig. 3. Results showed that SB-431542
increased androstenedione secretion at 0.1–2 mM,
but had no effect from 5 to 10 mM (data not
shown). Cell viability assessed on completion of the
144 h culture period showed that at concentrationswww.endocrinology-journals.org
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Figure 3 Androstenedione secretion from theca cells in the
presence of inhibin (10 ng/ml), SB-431542 (0.1–2 mM), or both
SB-431542 and inhibin (10 ng/ml), and follistatin (FS, 500 ng/ml)
over an accumulative period of 144 h. Data presented are the
averageGS.E.M. of four replicate wells, all from the same pool of
cells (nZ4 sheep pooled). *P!0.05, **P!0.01 and ***P!0.001
compared with the control group. The statistical significance of
SB-431542 alone and together with inhibin is also shown above
each treatment group as *P!0.05.
Inhibin removes inhibitory effects of activin . J M YOUNG and A S MCNEILLY 53of R5 mM SB-431542, cell viability decreased indicat-
ing that SB-431542 had a detrimental effect on these
cells (data not shown).
SB-431542 was added at doses ranging from 0.1 to
2 mM to maintain cell viability. Inhibin was used in
combination with SB-431542 to evaluate whether the
level of androgen secreted from cells was equal in cells
treated with either inhibitor. If inhibin was merely
causing androgen production by blocking the suppres-
sive effects of activin, then the expected result would be
equivalent to that observed when the chemical activin
receptor inhibitor was present. Interestingly, in this
experiment, the level of androstenedione secretion was
greater in cell cultures treated with both inhibin and
SB-431542 (Fig. 3).Follistatin inhibited activin suppression
Follistatin is a known antagonist of TGFb superfamily
members, including activin and BMPs, and was
originally identified from the follicular fluid of ovarian
follicles (Ueno et al. 1987). Follistatin (500 ng/ml) was
added to cultures and androstenedione production
measured (Fig. 3). The results show that the addition of
follistatin increased androgen accumulation over 144 h
in culture (P!0.001).www.endocrinology-journals.orgInhibitory Smads 6 and 7 increased androgen
production
Smads 6 and 7 are intracellular signaling molecules that
inhibit the signal transduction of BMP (Smad1/5/8),
or BMP and activin (Smad2/3) signaling respectively.
These inhibitory factors were transfected into theca
cultures using adenoviruses to manipulate Smad signal
transduction specifically. To establish the rate of
infection required, the adenovirus construct was titred
across concentrations from 10 to 100 pfu/cell seeded
(Fig. 4A). Results indicated that 10 pfu/cell was
sufficient to infect cells, and that at higher concen-
trations theca cell viability decreased. Overexpression
of Smad6 or 7 by infecting cells at 10, 50 and 100 pfu/
cell resulted in increased androstenedione production
from theca cells in culture over two consecutive 48 h
periods postinfection (Fig. 4A). It is not unexpected
that the effects of Smad7 are more pronounced than
those of Smad6 given that Smad7 inhibits both Smad1/
5/8 and Smad2/3 (rather than just Smad1/5/8 for
Smad6). BMPs have been previously shown to suppress
androstenedione production in bovine and ovine theca
cultures (Glister et al. 2005, Campbell et al. 2006), so
blocking BMP signaling with Smad6 would remove this
suppression which is presumably due to BMPs being
produced endogenously by the thecal cells themselves.
Adenovirus transfections were carried out at 10 pfu/
cell thereafter.
As expected, when activin was added to cells over-
expressing Smad6, the suppressive effects of activin
were not markedly altered. However, when Smad7 was
overexpressed, activin was unable to suppress androgen
production (P!0.001; Fig. 4B). Inhibin effects were not
affected by overexpression of either Smad6 or 7.Activin and inhibin modulate expression of genes
required for steroidogenesis
Given that activin and inhibin modulate androstene-
dione production from ovine theca cells in culture, we
assessed the effects of these factors on the expression
levels of components of the steroidogenic pathway
(Fig. 5). The expression of steroidogenic acute
regulatory protein (STAR), which is responsible for
transportation of cholesterol esters into the mito-
chondria for initiation of steroidogenesis, was dec-
reased in the presence of added activin (50 ng/ml),
and increased by SB-431542 alone (2 mM) and in
combination with inhibin (100 ng/ml; P!0.05). Acti-
vin alone did not affect the expression of CYP17
encoding 17a-hydroxylase (17aOH), whereas it was
increased by inhibin (P!0.05) and SB-431542
(P!0.001), and when added in combination, the
stimulatory effect was further enhanced (P!0.001). The
expression level of 3b-hydroxysteroid dehydrogenaseJournal of Molecular Endocrinology (2012) 48, 49–60
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Figure 4 (A) Androstenedione secretion from theca cells infected with either Smad6
or 7 for a 48 h period of culture. Cells were infected with 10, 50 and 100 pfu/cell
overnight before addition of new media and the beginning of the first 48 h period.
(B) Androstenedione production from theca cells infected with Smad6 or 7 in combination
with activin (10 ng/ml) and inhibin (10 ng/ml). Cells were infected with 10 pfu
adenovirus/cell overnight before addition of appropriate ligands. Data presented are the
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activin, while inhibin alone (P!0.01) and in com-
bination with SB-431542 (P!0.001) both increased the
expression of 3b-HSD. There were no significant effects
on the expression of cytochrome P450, family 11,
subfamily A and polypeptide 1 (CYP11A), indicating
that the effects of activin and inhibin are targeted
primarily to the expression of 3b-HSD.Expression of inhibitor of DNA-binding (ID) genes
ID1 expression levels were significantly reduced in the
presence of activin, inhibin and SB-431542 (P!0.05),
but the levels of ID2 did not change significantly for any
treatment group. ID3 and ID4 mRNA levels were below
detection levels (data not shown).Discussion
There is contradictory evidence for a role of activin in
follicle development, where some studies have shown
stimulatory effects (Li et al. 1995, Smitz et al. 1998,Journal of Molecular Endocrinology (2012) 48, 49–60Liu et al. 1999, Zhao et al. 2001, Thomas et al. 2003,
McLaughlin et al. 2010), while others suggest activin
inhibits development (Mizunuma et al. 1999, Ding et al.
2010), prevents luteinization (Myers et al. 2008), or has
no effect at all (Fortune et al. 2000). Moreover, the
concept of activin acting alone is far removed from the
in vivo situation where many other factors are present
that can antagonize and modulate the efficiency of
activin signaling.
Studies on ovarian somatic cells have been conducted
using media containing serum, which have been shown
to induce luteinization of cells, thus changing biological
functionality to principally the secretion of pro-
gesterone rather than androgens (Hillier et al. 1991b,
Shukovski et al. 1993, Wrathall & Knight 1995). In this
study, serum-free conditions were employed, and theca
cells were cultured for a maximum of 144 h in the
presence of low-dose LH to maintain androgen ster-
oidogenic capacity. This study extends on previous
findings in luteinized theca cells that activin A
suppresses androgen production from thecal cells
cultured in vitro without affecting cell viability (Hsueh
et al. 1987, Hillier & Miro 1993, Wrathall & Knight 1995).www.endocrinology-journals.org
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Figure 5 The expression of steroidogenic acute regulatory protein (STAR), 17a-hydroxyl-
ase (CYP17), 3b-hydroxysteroid dehydrogenase (3b-HSD), cholesterol side-chain
cleavage cytochrome P450 (CYP11A) and inhibitor of DNA binding 1 (ID1) was assessed in
theca cells cultured alone, or in the presence of activin (50 ng/ml), inhibin (100 ng/ml) and/or
SB-431542 (2 mM). Cells were cultured for a total of 64 h, whereby fresh ligand was added to
each well at 24 and 48 h and then an hour before RNA isolation. Data are the average
GS.E.M. for four replicate experiments (each experiment from a pool of cells harvested from
four to five sheep) containing four replicate wells per treatment. *P!0.05, **P!0.01 and
***P!0.001 were assessed by Student’s t-tests compared with the control group.
Inhibin removes inhibitory effects of activin . J M YOUNG and A S MCNEILLY 55In the ovary, a major factor modulating activin
bioactivity is inhibin, which is produced by granulosa
cells once follicles reach the preantral stage of
development (Roberts et al. 1993). It has been unclear
whether inhibin acts by simply blocking binding of
activin and BMPs to their receptors or it can elicit its
biological effects through an unidentified mechanism
not involving antagonism of activin/BMP receptors
since no signaling pathways have been identified withwww.endocrinology-journals.orginhibin bioactivity (Bernard et al. 2001, 2002). Associ-
ation of inhibin with the membrane-anchored proteo-
glycan, betaglycan (also known as TGFbRIII), has been
shown to increase the affinity of inhibin binding to
activin type II receptors (Lewis et al. 2000). However, it is
unclear if inhibin can elicit any signaling through
betaglycan in a manner similar to TGFb2 that utilizes
the small cytoplasmic domain of this receptor for
downstream signal transduction (Blobe et al. 2001).Journal of Molecular Endocrinology (2012) 48, 49–60
J M YOUNG and A S MCNEILLY . Inhibin removes inhibitory effects of activin56In bovine follicles, the abundance of betaglycan
increased approximately fivefold as bovine follicles
grew and decreased by 50% when follicles reached
the final stages of development, indicating an import-
ant role during the stages of development (Glister et al.
2010). Betaglycan is also found in granulosa and thecal
cells of sheep follicles (data not shown).
In this study, inhibin had a potent and robust
stimulatory effect on androstenedione production
when added to cell culture media alone. Furthermore,
it blocked the suppressive effects of activin added to
culture medium, confirming previous findings (Hillier
et al. 1991b, Hillier & Miro 1993, Wrathall & Knight
1995, Campbell & Baird 2001). The observation that
inhibin-treated cells produce considerably more andro-
gen than cells with no inhibin added indicates that
theca cells might produce activin and/or BMPs that
act in an autocrine manner to maintain the level of
androgen production at a basal level. The production
of activin bA subunit was investigated in these cultures,
and it was confirmed that theca cells produce activin bA
(data not shown).
Follistatin is produced by granulosa cells and is
abundant in follicles as soon as two layers of granulosa
cells have developed, and is maintained at high levels of
expression through all stages of follicle development up
to ovulation (Shimasaki et al. 1989, Nakatani et al. 1991,
Roberts et al. 1993, Braw-Tal et al. 1994, Tisdall et al.
1994, Izadyar et al. 1998, Sidis et al. 1998, Silva & Knight
1998). While follistatin was shown to have only a 10%
affinity for BMPs as for activins (Glister et al. 2004), it
was shown to reverse the suppressive effects of added
activin A, TGFb and BMP4/6/7 on thecal androgen
production (Hsueh et al. 1987, Hillier & Miro 1993,
Wrathall & Knight 1995, Cortvrindt et al. 1997, Glister
et al. 2005). In our study, when added in excess,
follistatin alone increased androgen production from
theca cells, supporting the concept that theca cells
produce activins/BMPs endogenously in vitro.
To further address this concept, we used the non-
signaling chemical activin receptor inhibitor SB-431542
as a comparative measure against inhibin (Bak et al.
2009). Androstenedione production was enhanced
from theca cultures to levels similar to those produced
by inhibin-treated cells, and an additive effect was
observed when inhibin and SB-431542 were added in
combination. This may be due to a dynamic mechanism
of inhibin action compared with the binding of the
chemical compound, or the fact that inhibin also
interferes with BMP signaling in addition to blocking
activin signaling since SB-431542 does not appear to
block BMPs effectively.
Intracellular inhibitory Smads were utilized to
investigate signaling mechanisms. The overexpression
of inhibitory Smads 6 and 7 alone (Fujii et al. 1999,
Nakao et al. 1999, Kaivo-Oja et al. 2003) resulted inJournal of Molecular Endocrinology (2012) 48, 49–60increased androstenedione production from theca
cultures over time. Moreover, the inhibition of signal-
ing by Smad7 was observed to have a more potent effect
than that caused by Smad6. This result is logical given
that Smad6 blocks BMP signaling through Smad1/5/8,
whereas Smad7 blocks both Smad1/5/8 and Smad2/3
pathways. Of importance, these results show that by
blocking activin and BMP signal transduction intra-
cellularly, theca cells produce greater amounts of
androstenedione than control cells over time.
As expected, since Smad6 affects the Smad1/5/8
pathway, it had no effect on the ability of activin A to
suppress androstenedione production and equally did
not block the stimulatory effects of inhibin. Activin
signaling was blocked by the overexpression of Smad7
but not by Smad6. Inhibin had an additive effect on
androstenedione production when Smad6 or 7 was
overexpressed. Taken together, these studies indicate
that inhibin acts similar to Smad signaling inhibitors
Smad6 or 7 by blocking Smad signal transduction and
increasing androgen production.
While activin and inhibin modulate theca cell
steroidogenesis, it has not been clear how this is
achieved. Gene expression analyses showed that activin
suppressed expression levels of STAR and 3b-HSD,
whilst inhibin and SB-431542 induced expression of
CYP17 and 3b-HSD. A previous study using a CYP17
promoter–luciferase reporter system in the H295R cell
line in vitro suggested that Smad3 directly inhibited
CYP17 promoter activity (Derebecka-Holysz et al. 2008),
but this was not replicated in this study with activin-
induced Smad2/3 in primary thecal cells. The most
potent and significant effects of activin, inhibin and
SB-431542 were found on the expression levels of
3b-HSD, indicating an important role for these factors
in modulating 3b-HSD abundance. 3b-HSD is required
for synthesis of both progesterone and androgens in
theca cells, and 17aOH is required for androgen
production. If inhibin stimulates or removes an
activin-induced inhibition of 3b-HSD expression, then
it would make sense that more progesterone would be
produced compared with androgens since the substrate
pregnenolone is being used to make progesterone,
therefore limiting the substrate available to 17aOH for
17-hydroxypregnenolone synthesis. However, past
research has not shown any effect of inhibin on
progesterone secretion from theca cells cultured in
media containing 5% FCS (Hillier et al. 1991b),
which may be due to luteinization. Testosterone is
synthesized from androstenedione in theca cells by
the enzyme 17b-hydroxysteroid, which has not been
assessed in these studies, as this enzyme is not thought
to be regulated by activins/inhibins due to the lack of
response in testosterone levels in these and other
studies (Shukovski et al. 1993). Furthermore, in this
study, activin, inhibin, SB-431542, Smad6 or 7 did notwww.endocrinology-journals.org
Inhibin removes inhibitory effects of activin . J M YOUNG and A S MCNEILLY 57have any effect on testosterone production (data not
shown).
Expression of the inhibitor of DNA-binding protein
genes (ID1–4) was assessed and the results agreed with
previous studies on granulosa cells from sheep follicles
(Hogg et al. 2010). Levels of mRNA encoding ID1 were
suppressed in the presence of activin A, but no changes
in ID2 expression were observed while ID3 and ID4 were
undetectable. In our previous study (Hogg et al. 2010),
activin decreased ID3 expression in granulosa cells;
moreover, this study also provided evidence that in
atretic follicles, ID3 and ID4 expression was partial or
absent. Since primary theca cells were cultured for a
short period of time and cells remained healthy and
viable, changes in ID2 were not expected. In other
experiments, BMPs increased ID1–4 expression in theca
cultures (data not shown). BMPs are functional in
the sheep follicle as evidenced by the presence of
p-Smad1/5/8 in theca and granulosa cells (Hogg et al.
2010) and from previous in vitro studies on bovine
thecal cells (Glister et al. 2010) and also our current
results using Smads 6 and 7, both of which inhibit BMP
signaling. Thus, it may be that in our culture system,
any endogenous BMPs that are being produced
are insufficient to maintain ID1–4 expression or are
counteracted by the endogenous activin being pro-
duced by the theca cultures themselves. The failure of
inhibin and the activin receptor blocker SB-431542 to
maintain or increase ID2 requires further investigation.
In humans, inhibin B is the predominant form of
inhibin present during the follicular phase of the cycle,
and inhibin A in the luteal phase (Groome et al. 1996).
However, inhibin B is not found in sheep ovaries. So,
these studies were carried out using only inhibin A
(McNeilly et al. 2002). In patients diagnosed with PCOS,
studies have shown that circulating inhibin B levels were
higher while activin A was lower in the follicular phase
(Anderson et al. 1998, Lockwood et al. 1998, Norman
et al. 2001, Shen et al. 2005). Inhibin A levels were
reported to be lower in the follicular fluid of PCOS
follicles compared with control follicles, and there were
no differences in levels of activin A and inhibin B levels
(Magoffin & Jakimiuk 1998). Activin has been pre-
viously shown to increase theca and granulosa cell
proliferation (Miro & Hillier 1996, Duleba et al. 2001).
In vitro studies using primary cultures of theca cells
from PCOS ovaries produced more androgens than
normal controls, had higher levels of steroid intermedi-
ates produced during steroidogenesis and had higher
levels of STAR, LHR, CYP17 and CYP11A expression
than in size-matched control follicles (Gilling-Smith
et al. 1994, Nelson et al. 1999, Wickenheisser et al. 2000,
Jakimiuk et al. 2001, Nelson et al. 2001). Ovaries from
PCOS women have also been shown to have 1.5-fold
higher expression of betaglycan than controls that
would enhance inhibin binding and ability to blockwww.endocrinology-journals.orgactivin action, whereas no difference in activin receptor
(types IA, IB, IIA and IIB) expression was detected (Zhu
et al. 2010). These alterations in inhibin and activin
concentrations coupled with increased thecal layers
may allow increased androgen production in PCOS
patients, caused not by an active excess secretion, but by
a reduction in the local inhibition of androgen
production by the reduced exposure to activins.
In conclusion, our present studies have confirmed
that the biological effects of activin on theca cell
androgen production are inhibitory, whereas inhibin
acts in an opposing manner by causing an increase in
the production of androgens. Furthermore, these
effects of activin are modulated through the Smad
signaling pathway that results in decreased levels of
STAR and 3b-HSD gene expression. The studies also
show that inhibin appears to act almost exclusively by
blocking the inhibitory action of activins, a concept
supported by the similar responses of increased
androgen production when activin action was blocked
by the activin receptor blocker SB-431542, the activin-
binding protein follistatin and the Smad2/3 signaling
pathway by Smad7. All the results also support the novel
concept that theca cells themselves produce activins,
and potentially BMPs which autoregulate androgen
production locally. As follicles develop and acquire
aromatase, they require more androgen precursor,
and this is induced by increased production of inhibin
by the granulosa cells, which then act to negate the
suppressive effects of thecal, and granulosa cell activins,
and BMPs. Therefore, inhibin does not stimulate
androgen production, but acts to remove the effects
of the inhibitor, activin, on suppressing CYP17 and
3b-HSD, thus allowing increased androgen production.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This study was funded by an MRC grant to A S M (G00007.01).Acknowledgements
We acknowledge Kirsten Hogg for her gift of primers for quantitative
RT-PCR assays. We also extend thanks to Joan Docherty and staff at
the Marshall Building for help with all the animal work.References
Anderiesz C & Trounson AO 1995 The effect of testosterone on the
maturation and developmental capacity of murine oocytes in vitro.
Human Reproduction 10 2377–2381.Journal of Molecular Endocrinology (2012) 48, 49–60
J M YOUNG and A S MCNEILLY . Inhibin removes inhibitory effects of activin58Anderson RA, Groome NP & Baird DT 1998 Inhibin A and inhibin B in
women with polycystic ovarian syndrome during treatment with
FSH to induce mono-ovulation. Clinical Endocrinology 48 577–584.
(doi:10.1046/j.1365-2265.1998.00442.x)
Bak B, Carpio L, Kipp JL, Lamba P, Wang Y, Ge RS, Hardy MP, Mayo
KE & Bernard DJ 2009 Activins regulate 17beta-hydroxysteroid
dehydrogenase type I transcription in murine gonadotrope cells.
Journal of Endocrinology 201 89–104. (doi:10.1677/JOE-08-0460)
Bernard DJ, Chapman SC & Woodruff TK 2001 An emerging role
for co-receptors in inhibin signal transduction. Molecular and
Cellular Endocrinology 180 55–62. (doi:10.1016/S0303-7207(01)
00500-7)
Bernard DJ, Chapman SC & Woodruff TK 2002 Inhibin binding
protein (InhBP/p120), betaglycan, and the continuing search for
the inhibin receptor. Molecular Endocrinology 16 207–212. (doi:10.
1210/me.16.2.207)
Billiar RB, Richardson D, Anderson E, Mahajan D & Little B 1985 The
effect of chronic and acyclic elevation of circulating androstene-
dione or estrone concentrations on ovarian function in the rhesus
monkey. Endocrinology 116 2209–2220. (doi:10.1210/endo-116-6-
2209)
Billig H, Furuta I & Hsueh AJ 1993 Estrogens inhibit and
androgens enhance ovarian granulosa cell apoptosis. Endocrinology
133 2204–2212. (doi:10.1210/en.133.5.2204)
Blobe GC, Liu X, Fang SJ, How T & Lodish HF 2001 A novel
mechanism for regulating transforming growth factor beta
(TGF-beta) signaling. Functional modulation of type III TGF-beta
receptor expression through interaction with the PDZ domain
protein, GIPC. Journal of Biological Chemistry 276 39608–39617.
(doi:10.1074/jbc.M106831200)
Braw-Tal R, Tisdall DJ, Hudson NL, Smith P & McNatty KP 1994
Follistatin but not alpha or beta A inhibin subunit mRNA is
expressed in ovine fetal ovaries in late gestation. Journal of Molecular
Endocrinology 13 1–9. (doi:10.1677/jme.0.0130001)
Campbell BK & Baird DT 2001 Inhibin A is a follicle stimulating
hormone-responsive marker of granulosa cell differentiation, which
has both autocrine and paracrine actions in sheep. Journal of
Endocrinology 169 333–345. (doi:10.1677/joe.0.1690333)
Campbell BK, Scaramuzzi RJ & Webb R 1996 Induction and
maintenance of oestradiol and immunoreactive inhibin production
with FSH by ovine granulosa cells cultured in serum-free media.
Journal of Reproduction and Fertility 106 7–16. (doi:10.1530/jrf.0.
1060007)
Campbell BK, Baird DT & Webb R 1998 Effects of dose of LH on
androgen production and luteinization of ovine theca cells
cultured in a serum-free system. Journal of Reproduction and Fertility
112 69–77. (doi:10.1530/jrf.0.1120069)
Campbell BK, Souza CJ, Skinner AJ, Webb R & Baird DT 2006
Enhanced response of granulosa and theca cells from sheep
carriers of the FecB mutation in vitro to gonadotropins and bone
morphogenic protein-2, -4, and -6. Endocrinology 147 1608–1620.
(doi:10.1210/en.2005-0604)
Cortvrindt R, Smitz J & Van Steirteghem AC 1997 Assessment of the
need for follicle stimulating hormone in early preantral mouse
follicle culture in vitro. Human Reproduction 12 759–768. (doi:10.
1093/humrep/12.4.759)
Daniel SA & Armstrong DT 1986 Androgens in the ovarian
microenvironment. Seminars in Reproductive Endocrinology 4 89–100.
(doi:10.1055/s-2007-1022489)
Derebecka-Holysz N, Lehmann TP, Holysz M & Trzeciak WH 2008
Smad3 inhibits SF-1-dependent activation of the CYP17 promoter in
H295R cells. Molecular and Cellular Biochemistry 307 65–71. (doi:10.
1007/s11010-007-9585-4)
Ding CC, Thong KJ, Krishna A & Telfer EE 2010 Activin A inhibits
activation of human primordial follicles in vitro. Journal of Assisted
Reproduction and Genetics 27 141–147. (doi:10.1007/s10815-010-
9395-6)Journal of Molecular Endocrinology (2012) 48, 49–60Duleba AJ, Pehlivan T, Carbone R & Spaczynski RZ 2001 Activin
stimulates proliferation of rat ovarian thecal–interstitial cells. Biology
of Reproduction 65 704–709. (doi:10.1095/biolreprod65.3.704)
Faiman C, Reyes FI, Dent DW, Fuller GB, Hobson WC & Thliveris JA
1988 Effects of long-term testosterone exposure on ovarian
function and morphology in the rhesus monkey. Anatomical Record
222 245–251. (doi:10.1002/ar.1092220305)
Fortune JE, Cushman RA, Wahl CM & Kito S 2000 The primordial to
primary follicle transition. Molecular and Cellular Endocrinology 163
53–60. (doi:10.1016/S0303-7207(99)00240-3)
Fujii M, Takeda K, Imamura T, Aoki H, Sampath TK, Enomoto S,
Kawabata M, Kato M, Ichijo H & Miyazono K 1999 Roles of bone
morphogenetic protein type I receptors and Smad proteins in
osteoblast and chondroblast differentiation. Molecular Biology of the
Cell 10 3801–3813.
Gilling-Smith C, Willis DS, Beard RW & Franks S 1994 Hypersecretion
of androstenedione by isolated thecal cells from polycystic ovaries.
Journal of Clinical Endocrinology and Metabolism 79 1158–1165.
(doi:10.1210/jc.79.4.1158)
Gilling-Smith C, Story H, Rogers V & Franks S 1997 Evidence for a
primary abnormality of thecal cell steroidogenesis in the polycystic
ovary syndrome. Clinical Endocrinology 47 93–99. (doi:10.1046/j.
1365-2265.1997.2321049.x)
Glister C, Kemp CF & Knight PG 2004 Bone morphogenetic protein
(BMP) ligands and receptors in bovine ovarian follicle cells: actions
of BMP-4, -6 and -7 on granulosa cells and differential modulation
of Smad-1 phosphorylation by follistatin. Reproduction 127 239–254.
(doi:10.1530/rep.1.00090)
Glister C, Richards SL & Knight PG 2005 Bone morphogenetic
proteins (BMP) -4, -6, and -7 potently suppress basal and luteinizing
hormone-induced androgen production by bovine theca interna
cells in primary culture: could ovarian hyperandrogenic dysfunc-
tion be caused by a defect in thecal BMP signaling? Endocrinology 146
1883–1892. (doi:10.1210/en.2004-1303)
Glister C, Satchell L & Knight PG 2010 Changes in expression of bone
morphogenetic proteins (BMPs), their receptors and inhibin
co-receptor betaglycan during bovine antral follicle development:
inhibin can antagonize the suppressive effect of BMPs on thecal
androgen production. Reproduction 140 699–712. (doi:10.1530/
REP-10-0216)
Groome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP &
McNeilly AS 1996 Measurement of dimeric inhibin B throughout
the human menstrual cycle. Journal of Clinical Endocrinology and
Metabolism 81 1401–1405. (doi:10.1210/jc.81.4.1401)
Hillier SG & Ross GT 1979 Effects of exogenous testosterone on
ovarian weight, follicular morphology and intraovarian pro-
gesterone concentration in estrogen-primed hypophysectomized
immature female rats. Biology of Reproduction 20 261–268. (doi:10.
1095/biolreprod20.2.261)
Hillier SG & Miro F 1993 Inhibin, activin, and follistatin. Potential
roles in ovarian physiology. Annals of the New York Academy of Sciences
687 29–38. (doi:10.1111/j.1749-6632.1993.tb43850.x)
Hillier SG, Yong EL, Illingworth PJ, Baird DT, Schwall RH & Mason AJ
1991a Effect of recombinant activin on androgen synthesis in
cultured human thecal cells. Journal of Clinical Endocrinology and
Metabolism 72 1206–1211. (doi:10.1210/jcem-72-6-1206)
Hillier SG, Yong EL, Illingworth PJ, Baird DT, Schwall RH & Mason AJ
1991b Effect of recombinant inhibin on androgen synthesis in
cultured human thecal cells. Molecular and Cellular Endocrinology 75
R1–R6. (doi:10.1016/0303-7207(91)90234-J)
Hogg K, Etherington SL, Young JM, McNeilly AS & Duncan WC 2010
Inhibitor of differentiation (Id) genes are expressed in the
steroidogenic cells of the ovine ovary and are differentially
regulated by members of the transforming growth factor-beta
family. Endocrinology 151 1247–1256. (doi:10.1210/en.2009-0914)
Hsueh AJ, Dahl KD, Vaughan J, Tucker E, Rivier J, Bardin CW & Vale W
1987 Heterodimers and homodimers of inhibin subunits havewww.endocrinology-journals.org
Inhibin removes inhibitory effects of activin . J M YOUNG and A S MCNEILLY 59different paracrine action in the modulation of luteinizing
hormone-stimulated androgen biosynthesis. PNAS 84 5082–5086.
(doi:10.1073/pnas.84.14.5082)
Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD,
Laping NJ & Hill CS 2002 SB-431542 is a potent and specific
inhibitor of transforming growth factor-beta superfamily type I
activin receptor-like kinase (ALK) receptors ALK4, ALK5, and
ALK7. Molecular Pharmacology 62 65–74. (doi:10.1124/mol.62.1.65)
Izadyar F, Dijkstra G, Van Tol HT, Van den Eijnden-van Raaij AJ, Van
den Hurk R, Colenbrander B & Bevers MM 1998 Immunohisto-
chemical localization and mRNA expression of activin, inhibin,
follistatin, and activin receptor in bovine cumulus–oocyte
complexes during in vitro maturation. Molecular Reproduction and
Development 49 186–195. (doi:10.1002/(SICI)1098-2795(199802)
49:2!186::AID-MRD9O3.0.CO;2-L)
Jakimiuk AJ, Weitsman SR, Navab A & Magoffin DA 2001 Luteinizing
hormone receptor, steroidogenesis acute regulatory protein, and
steroidogenic enzyme messenger ribonucleic acids are over-
expressed in thecal and granulosa cells from polycystic ovaries.
Journal of Clinical Endocrinology and Metabolism 86 1318–1323.
(doi:10.1210/jc.86.3.1318)
Kaivo-Oja N, Bondestam J, Kamarainen M, Koskimies J, Vitt U,
Cranfield M, Vuojolainen K, Kallio JP, Olkkonen VM, Hayashi M
et al. 2003 Growth differentiation factor-9 induces Smad2 activation
and inhibin B production in cultured human granulosa–luteal cells.
Journal of Clinical Endocrinology and Metabolism 88 755–762. (doi:10.
1210/jc.2002-021317)
Laufer N, DeCherney AH, Haseltine FP & Behrman HR 1984 Steroid
secretion by the human egg–corona–cumulus complex in culture.
Journal of Clinical Endocrinology and Metabolism 58 1153–1157.
(doi:10.1210/jcem-58-6-1153)
Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM
& Vale W 2000 Betaglycan binds inhibin and can mediate functional
antagonism of activin signalling. Nature 404 411–414. (doi:10.1038/
35006129)
Li R, Phillips DM & Mather JP 1995 Activin promotes ovarian follicle
development in vitro. Endocrinology 136 849–856. (doi:10.1210/en.
136.3.849)
Liu X, Andoh K, Abe Y, Kobayashi J, Yamada K, Mizunuma H & Ibuki Y
1999 A comparative study on transforming growth factor-beta
and activin A for preantral follicles from adult, immature, and
diethylstilbestrol-primed immature mice. Endocrinology 140
2480–2485. (doi:10.1210/en.140.6.2480)
Lockwood GM, Muttukrishna S, Groome NP, Matthews DR & Ledger
WL 1998 Mid-follicular phase pulses of inhibin B are absent in
polycystic ovarian syndrome and are initiated by successful
laparoscopic ovarian diathermy: a possible mechanism regulating
emergence of the dominant follicle. Journal of Clinical Endocrinology
and Metabolism 83 1730–1735. (doi:10.1210/jc.83.5.1730)
Magoffin DA & Jakimiuk AJ 1998 Inhibin A, inhibin B and activin A
concentrations in follicular fluid from women with polycystic ovary
syndrome. Human Reproduction 13 2693–2698.
McLaughlin M, Bromfield JJ, Albertini DF & Telfer EE 2010 Activin
promotes follicular integrity and oogenesis in cultured pre-antral
bovine follicles. Molecular Human Reproduction 16 644–653. (doi:10.
1093/molehr/gaq021)
McNeilly AS, Souza CJ, Baird DT, Swanston IA, McVerry J, Crawford J,
Cranfield M & Lincoln GA 2002 Production of inhibin A not B in
rams: changes in plasma inhibin A during testis growth, and
expression of inhibin/activin subunit mRNA and protein in adult
testis. Reproduction 123 827–835. (doi:10.1530/rep.0.1230827)
Miro F & Hillier SG 1996 Modulation of granulosa cell deoxyribo-
nucleic acid synthesis and differentiation by activin. Endocrinology
137 464–468. (doi:10.1210/en.137.2.464)
Mizunuma H, Liu X, Andoh K, Abe Y, Kobayashi J, Yamada K, Yokota H,
Ibuki Y & Hasegawa Y 1999 Activin from secondary follicles causes
small preantral follicles to remain dormant at the resting stage.
Endocrinology 140 37–42. (doi:10.1210/en.140.1.37)www.endocrinology-journals.orgMurray AA, Gosden RG, Allison V & Spears N 1998 Effect of androgens
on the development of mouse follicles growing in vitro. Journal of
Reproduction and Fertility 113 27–33. (doi:10.1530/jrf.0.1130027)
Myers M, van den Driesche S, McNeilly AS & Duncan WC 2008 Activin
A reduces luteinisation of human luteinised granulosa cells and has
opposing effects to human chorionic gonadotropin in vitro.
Journal of Endocrinology 199 201–212. (doi:10.1677/JOE-08-0302)
Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K &
Iwamoto I 1999 Transient gene transfer and expression of Smad7
prevents bleomycin-induced lung fibrosis in mice. Journal of Clinical
Investigation 104 5–11. (doi:10.1172/JCI6094)
Nakatani A, Shimasaki S, Depaolo LV, Erickson GF & Ling N 1991
Cyclic changes in follistatin messenger ribonucleic acid and its
protein in the rat ovary during the estrous cycle. Endocrinology 129
603–611. (doi:10.1210/endo-129-2-603)
Nelson VL, Legro RS, Strauss JF III & McAllister JM 1999 Augmented
androgen production is a stable steroidogenic phenotype
of propagated theca cells from polycystic ovaries. Molecular
Endocrinology 13 946–957. (doi:10.1210/me.13.6.946)
Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS,
Strauss JF III & McAllister JM 2001 The biochemical basis for
increased testosterone production in theca cells propagated from
patients with polycystic ovary syndrome. Journal of Clinical
Endocrinology and Metabolism 86 5925–5933. (doi:10.1210/jc.86.12.
5925)
Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, Asano T,
Fujishiro M, Legro RS, Kimball SR, Strauss JF III & McAllister JM
2005 Alterations in mitogen-activated protein kinase kinase and
extracellular regulated kinase signaling in theca cells contribute to
excessive androgen production in polycystic ovary syndrome.
Molecular Endocrinology 19 379–390. (doi:10.1210/me.2004-0178)
Norman RJ, Milner CR, Groome NP & Robertson DM 2001 Circulating
follistatin concentrations are higher and activin concentrations
are lower in polycystic ovarian syndrome. Human Reproduction 16
668–672. (doi:10.1093/humrep/16.4.668)
Roberts VJ, Barth S, el-Roeiy A & Yen SS 1993 Expression of
inhibin/activin subunits and follistatin messenger ribonucleic acids
and proteins in ovarian follicles and the corpus luteum during the
human menstrual cycle. Journal of Clinical Endocrinology and
Metabolism 77 1402–1410. (doi:10.1210/jc.77.5.1402)
Shen ZJ, Chen XP & Chen YG 2005 Inhibin B, activin A, and follistatin
and the pathogenesis of polycystic ovary syndrome. International
Journal of Gynaecology and Obstetrics 88 336–337. (doi:10.1016/j.ijgo.
2004.12.024)
Shimasaki S, Koga M, Buscaglia ML, Simmons DM, Bicsak TA & Ling N
1989 Follistatin gene expression in the ovary and
extragonadal tissues. Molecular Endocrinology 3 651–659. (doi:10.
1210/mend-3-4-651)
Shukovski L, Dyson M & Findlay JK 1993 The effects of follistatin,
activin and inhibin on steroidogenesis by bovine thecal cells.
Molecular and Cellular Endocrinology 97 19–27. (doi:10.1016/0303-
7207(93)90207-Z)
Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T & Schneyer AL 1998
Characterization of inhibin/activin subunit, activin receptor, and
follistatin messenger ribonucleic acid in human and mouse oocytes:
evidence for activin’s paracrine signaling from granulosa cells to
oocytes. Biology of Reproduction 59 807–812. (doi:10.1095/biolre-
prod59.4.807)
Silva CC & Knight PG 1998 Modulatory actions of activin-A and
follistatin on the developmental competence of in vitro-matured
bovine oocytes. Biology of Reproduction 58 558–565. (doi:10.1095/
biolreprod58.2.558)
Smitz J, Cortvrindt R, Hu Y & Vanderstichele H 1998 Effects of
recombinant activin A on in vitro culture of mouse preantral
follicles. Molecular Reproduction and Development 50 294–304.
(doi:10.1002/(SICI)1098-2795(199807)50:3!294::AID-MRD5O
3.0.CO;2-E)Journal of Molecular Endocrinology (2012) 48, 49–60
J M YOUNG and A S MCNEILLY . Inhibin removes inhibitory effects of activin60Tesarik J & Mendoza C 1995 Nongenomic effects of 17 beta-estradiol
on maturing human oocytes: relationship to oocyte developmental
potential. Journal of Clinical Endocrinology andMetabolism 801438–1443.
(doi:10.1210/jc.80.4.1438)
Tetsuka M & Hillier SG 1997 Differential regulation of aromatase and
androgen receptor in granulosa cells. Journal of Steroid Biochemistry
and Molecular Biology 61 233–239. (doi:10.1016/S0960-0760(97)
80017-9)
Thomas FH, Armstrong DG & Telfer EE 2003 Activin promotes oocyte
development in ovine preantral follicles in vitro. Reproductive Biology
and Endocrinology 1 76. (doi:10.1186/1477-7827-1-76)
Tisdall DJ, Hudson N, Smith P & McNatty KP 1994 Localization of
ovine follistatin and alpha and beta A inhibin mRNA in the sheep
ovary during the oestrous cycle. Journal of Molecular Endocrinology 12
181–193. (doi:10.1677/jme.0.0120181)
Ueno N, Ling N, Ying S-Y, Esch F, Shimasaki S & Guillemin R 1987
Isolation and partial characterization of follistatin: a single-chain Mr
35 000 monomeric protein that inhibits the release of follicle-
stimulating hormone. PNAS 84 8282–8286. (doi:10.1073/pnas.84.
23.8282)
Vendola KA, Zhou J, Adesanya OO, Weil SJ & Bondy CA 1998 Androgens
stimulate early stages of follicular growth in the primate ovary.
Journal of Clinical Investigation 101 2622–2629. (doi:10.1172/JCI2081)
Vendola K, Zhou J, Wang J & Bondy CA 1999 Androgens promote
insulin-like growth factor-I and insulin-like growth factor-I receptor
gene expression in the primate ovary. Human Reproduction 14
2328–2332. (doi:10.1093/humrep/14.9.2328)
Weil S, Vendola K, Zhou J & Bondy CA 1999 Androgen and follicle-
stimulating hormone interactions in primate ovarian follicle
development. Journal of Clinical Endocrinology and Metabolism 84
2951–2956. (doi:10.1210/jc.84.8.2951)Journal of Molecular Endocrinology (2012) 48, 49–60Wiater E & Vale W 2003 Inhibin is an antagonist of bone
morphogenetic protein signaling. Journal of Biological Chemistry 278
7934–7941. (doi:10.1074/jbc.M209710200)
Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF III &
McAllister JM 2000 Differential activity of the cytochrome P450
17alpha-hydroxylase and steroidogenic acute regulatory protein
gene promoters in normal and polycystic ovary syndrome theca
cells. Journal of Clinical Endocrinology and Metabolism 85 2304–2311.
(doi:10.1210/jc.85.6.2304)
Wrathall JH & Knight PG 1995 Effects of inhibin-related peptides and
oestradiol on androstenedione and progesterone secretion by
bovine theca cells in vitro. Journal of Endocrinology 145 491–500.
(doi:10.1677/joe.0.1450491)
Young JM & McNeilly AS 2010 Theca: the forgotten cell of the
ovarian follicle. Reproduction 140 489–504. (doi:10.1530/
REP-10-0094)
Zhao J, Taverne MA, van der Weijden GC, Bevers MM & van den Hurk
R 2001 Effect of activin A on in vitro development of rat preantral
follicles and localization of activin A and activin receptor II. Biology
of Reproduction 65 967–977. (doi:10.1095/biolreprod65.3.967)
Zhu R, Zhou X, Chen Y, Qiu C, Xu W & Shen Z 2010 Aberrantly
increased mRNA expression of betaglycan, an inhibin co-receptor
in the ovarian tissues in women with polycystic ovary syndrome.
Journal of Obstetrics and Gynaecology Research 36 138–146. (doi:10.
1111/j.1447-0756.2009.01103.x)
Received in final form 18 October 2011
Accepted 14 November 2011
Made available online as an Accepted Preprint 14 November 2011www.endocrinology-journals.org
